demonstrated that BV reduced the absolute number of three MDSC subtypes (CD11b+CD33+CD14−CD34+HLA-DR−; M-MDSC and G-MDSC) coinciding with reduced soluble Arg-1 levels and restored the entire T-cell populations in HL patients; indicating its therapeutic use as MDSC targeting agent (65). Here, CD33 is linked to Hodgkins lymphoma.